Stephen Saad's Aspen Pharmacare predicts double-digit growth despite tough first half
Aspen Pharmacare reported a steep drop in first-half earnings due to one-off restructuring costs but expects double-digit profit growth by year-end.
Skip to content
Aspen Pharmacare reported a steep drop in first-half earnings due to one-off restructuring costs but expects double-digit profit growth by year-end.
These industry giants have built pharmaceutical empires that generate billions in revenue while making healthcare more affordable and widely available.